GSK Agrees To Buy US Respiratory Drug Biz For Up To $1.4B
GSK said Tuesday that it has agreed to buy Aiolos Bio Inc., a clinical-stage asthma drug developer, in a deal that could reach $1.4 billion as the British pharmaceuticals giant looks to...To view the full article, register now.
Already a subscriber? Click here to view full article